Member Info for crumbs

The $100 million is just an upfront and near-term milestones payment... not bad that for a preclinical product.

Immunocore certainly knows how to get deals... scancell tell us deals are only possible on data... SCIB1 has better data than Immtacs behind it already.... go figure!

Very interesting... sounds like a conversation has been had before this visit to China... maybe something is coming from the east after all... well apart from the the big freeze

Yeah seems like an opportunity for UK... RG built up good relationships with Gov agencies pushing UK biotech:

This article also worth a read:

Biotech companies without revenues, let alone profits, will now be allowed to apply for listings in the city under the new rules. Some 10 companies — mostly Chinese, including the Temasek backed Innovent Biologics and Shanghai Henlius Biotech — are already planning floats and some have dropped U.S. IPO plans in favor of listing closer to home.

The result however is a scramble for experts in a city whose financiers have limited experience with science.

Just 3 percent of all Hong Kong-listed stocks, by capitalization, come from so-called "new economy" sectors — tech as well as biotech — according to a report last year by Hong Kong Exchanges and Clearing, the bourse operator.

That compared with 60 percent for Nasdaq and 47 percent for the New York Stock Exchange.

Several bankers, investors and industry executives estimated that the city currently had fewer than 20 experienced biotech and biopharma bankers.
https://www.cnbc.com/2018/04/29/hong-kong-scrambles-for-talent-in-battle-for-nasdaqs-biotech-crown.html

Also from booms article tweet relating to the visit that scancell retweeted:

BIA CEO, Steve Bates, said: “This trip is the centrepiece of the BIA’s ramp up of engagement East in 2018. Building on our China Special Interest Group we are seeking to increase the number of UK biotech companies collaborating with, generating revenue from, and receiving investment from the Chinese market. In Hong Kong I am exploring how we can jointly build the life science analytical capability needed for global liquidity - and make dual listing - or similar - a practical reality for UK companies seeking investment there.

“With President Trump’s new Committee on Foreign Investment in the U.S (CFIUS) regulations applying to Chinese life science investments into the US on deals that close after this weekend, I am also keen to understand their impact real time on Chinese investor appetite for globally relevant non-US biotech opportunities - like the UK.”

The BIA formed the China Special Interest Group with the China-Britain Business Council (CBBC), and supported by the Department for International Trade (DIT), to provide a discussion platform for BIA and CBBC members in the Biotech sector, exploring the opportunities for business growth in and with China, via trade and investment.

https://www.bioindustry.org/news-listing/bia-heads-to-hong-kong-and-china-to-explore-future-collaboration-on-weekend-new-us-regulations-on-biotech-investment-come-into-force.html

It is good to see RG still putting in and shows he is still very much a part of the scancell team and story... and quite possibly is meeting contacts he already built up a relationship with over in China I like to think the scancell approach would appeal to Chinese investors and that they would not be so put off by the novelty which seems to me to be the case with western investors ....but till we know we know nothing :) nothing apart from scancell is super busy and not just in the lab.

These events are definitely not a waste of time they are frontline communication .... The China one excites me most as seems we are one of the select few to get to present there, by invite and what comes after as in who wants to meet or stay in touch or dare we hope has already been in contact and wants closer talks (we do not know if we already have China contacts-we may do) ....I seem to remember SCIB1 was once presented at some event in China a few years ago ?... so yeah nothing money wise ever seems to have come our way from such events but I'm sure interested contacts have been made via them over the years...and as has been stated on here China has its own war with Cancer and Cancer is not going anywhere it is only going to increase in incidence so I think the people attending over there will be very interested in scancell

An internet connection and a kid with a phone :)

The presentation document is already on the website

http://www.scancell.co.uk/file-manager/PDFs/scancell-lsx-presentation_november-2018.pdf

Did not see the CH live presentation but interesting from that PDF is the Nano-vesicle delivery under evaluation seems to cover all ImmunoBody platform now and not just SCIB2
I'd speculate we are quite far into that 'evaluation' and it is looking to be the way ahead... does seem BioNtech are looking at modi2 as well as modi1 for TCR too...

Ahh ok crikey, I'm sure that wasn't easy

Were you really a captive in a religious cult?

I should say to present not just attend...

'Presenting Companies are hand-picked by BioCentury and BayHelix based on rigorous selection criteria, including investor validation, upcoming milestones, unpartnered assets and innovative science.'

https://www.biocentury.com/conferences/china-healthcare-summit-2018/presenters

Scancell have been 'invited' to attend :

China's Globally Facing Future: How China’s healthcare pathfinders are leveraging the nation’s innovation, policy initiatives and access to capital markets in HK and domestic exchanges to build a globally facing industry. Five years ago, the first China Healthcare Summit asked how the nation would build the “Bridge to Innovation.” In 2018, we examine how China is now actually building the Bridge to Global Healthcare. A full two-day program highlighted by dialog among China-facing biotech innovators and their globally-facing Chinese counterparts.

The China Summit is a VIP-only event for busy biopharma and life sciences executives and investors to get a first-hand look at the innovation, business and policy transformations taking place in China. The conference is THE place to meet the right Chinese investors and partners in an intimate setting. The China Summit will include:

Two days of strategic sessions and keynotes tailored to help executives understand emerging opportunities and challenges in China.
The China Summit report created by Insights Partner, McKinsey & Company. This exclusive analysis documents market trends and identifies business imperatives for biopharma and life sciences companies doing business in China.
New for 2018: For the 1st time, the China Summit will feature a presenting company track to showcase biotechs from China, Asia and the West, hand-picked by BioCentury and BayHelix.
New for 2018: A 1x1 meeting system will allow attendees to arrange face-to-face discussions with investors and corporate delegates.
Three VIP receptions to network with senior-level executives and investors.
The annual BayHelix Awards ceremony and lunch to celebrate R&D and commercial achievements in China.
Multiple networking breaks throughout the event to meet peers across the China innovation ecosystem.
https://www.biocentury.com/conferences/china-healthcare-summit-2018

Busy scancell off to China to flog the wares

https://twitter.com/BioPharmaJosh/status/1059465366886326272

OK, DA :)
I think we are part of a British contingent of bios over in Denmark ...It's nice to know when we are at these events so is worth them tweeting them otherwise we all get thinking nothing is going on lol and AIM with its microsecond attention span does not like that!.... It sounds like scancell are on the radar of all the pharmas would be interested in scancell though going off what our BOD said at AGM so possibly they all being updated about modi 2 now and where scancell see that fitting in with future moditope combinations etc...

Still very much ARM holdings?..... and scancell then becoming too expensive for any pharma to buy outright...

I don't know if we have been at this one before... hardly worth an RNS as scancell rightly attend lots of these events over the years but yes this does look like a biggie and is mostly all about partnerships no denying we have in our pipeline what most pharmas want.. do they want enough though lol or at scancells terms and asking prices... that we dunno... though seems L....D Lindy Durrant :) is very much for holding onto complete moditope IP for as long as possible ...we have Glycan MABs to push though

We have a scancell tweet too!
https://twitter.com/scancellpharma/status/1059717496465514496

Jesus Christ .... our saviour in San Diego

CHeese and LemonaDe